Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-RTS-hIL-12 with activator ligand in unresectable melanoma
NCT01397708Phase 2Completed
- Sponsor
- Alaunos Therapeutics
- Start
- Aug 2011
- Primary completion
- Sep 2014
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of ad-rts-hil-12 in melanoma, sponsored by Alaunos Therapeutics. Started Aug 2011; status: completed.
02
Drugs
ad-rts-hil-12
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01397708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01397708.